ULTIMO clinical trial in breast cancer.

The ULTIMO phase three clinical trial is focused on evaluating the efficacy and safety of two “boost” strategies (additional dose of radiotherapy) administered after breast volume radiotherapy in patients operated with curative intent for breast cancer. This trial seeks to determine which of the two strategies provides better results in terms of local cancer control and side effects.

The two boost techniques being compared include, on the one hand, a traditional approach with an additional dose of focused radiotherapy and, on the other, the use of more advanced techniques that could allow a more precise and less invasive administration of the treatment.

The main objective of the study is to analyze not only the efficacy of cancer control at the site of the operation, but also to evaluate the quality of life of the patients and the possible adverse effects of each of the strategies. The results of the ULTIMO trial could provide valuable information on how to optimize adjuvant treatment in patients with breast cancer, thus improving the clinical results and general well-being of the patients.